Niko Kley explains the concept of allosteric molecular glues, and how Orionis is also trying to design cytokines that are selectively activated at the site of tumors.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
​
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
​
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
​
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A
.png){kind=logo}
